Dr. Kanwar is a Professor of Medicine at the University of Chicago and Director of their Heart Failure and Pulmonary Hypertension program. She currently serves as the Associate Editor for MCS for the Journal of Heart and Lung Transplantation. With nearly 200 peer-reviewed publications, her area of research focus includes outcomes research in cardiogenic shock, temporary and durable mechanical circulatory support, as well as pulmonary hypertension.

Sean Lal is an Academic (basic sciences and translational research) in the Faculty of Medicine and Health at the University of Sydney and a Consultant Cardiologist at Royal Prince Alfred Hospital, where he is the Director of Acute Heart Failure Services.

Perry Elliott is director of the UCL Institute of Cardiovascular Science and a consultant cardiologist at St. Bartholomew's Hospital London. He is past chairman of the ESC Heart Academy, the ESC Council on Cardiovascular Genomics, the ESC Working Group on Myocardial and Pericardial Diseases and the Executive Committee for the European Outcomes Research Programme registry on cardiomyopathies. He is an executive Editor for the European Heart Journal. For almost 30 years, he has led numerous international consortia and has made substantial scientific and policy contributions including clinical risk tools, discovery of rare and common genetic causes of inherited heart conditions, and US and European Practice guidelines. He has published more than 800 articles in the field and was listed in Clarivate’s annual ‘Highly Cited Researchers List’ in 2024 and 2025. He is founder and chair of the International Cardiomyopathy Network and President of Cardiomyopathy UK.

Prof Julie McMullen is the Deputy Director of the Heart Research Institute (HRI) in Syndey and leads the Heart Muscle Laboratory. Julie is recognised internationally for research that has defined the molecular distinction between physiological and pathological heart enlargement (cardiac hypertrophy) in preclinical models of health and disease. She discovered that a signalling pathway activated with exercise (IGF1-PI3K pathway) was critical for physiological hypertrophy (e.g. athlete’s heart) but not pathological hypertrophy (e.g. setting of hypertension). She subsequently developed novel therapies based on her findings in genetic mouse models involving adeno-associated virus (AAV) technology, RNA interference approaches, and small molecules. Other research interests include atrial fibrillation, heart-organ cross-talk and cancer therapy-induced cardiotoxicity. She is an Associate Editor of a new Nature Portfolio Journal-NPJ-Cardiovascular Health, and serves on several editorial boards. She is a Fellow of the AHA and ISHR, and is President of the ISHR-Australasian section.

Muthiah Vaduganathan, MD MPH FACC FHFA is a cardiologist and clinical trialist at Brigham and Women’s Hospital and Harvard Medical School. He is co-director of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital. He serves as an Associate Editor of JACC and as US national ambassador to the ESC Heart Failure Association. His research focuses on drug development, clinical trials, and implementation of cardio-kidney-metabolic therapies. He has authored or co-authored more than 850 peer-reviewed publications and is recognized as a Clarivate Highly Cited Researcher. He participates on study leadership of ongoing advanced-phase trials in cardio-kidney-metabolism and heart failure.

David Jenkins is a Consultant Cardiothoracic Surgeon at Papworth Hospital, Cambridge, UK. He graduated from medical school at the University of London in 1989, with a first class intercalated BSc in Physiology, and trained in surgery in London. Following a 2-year formal research period investigating ischaemic preconditioning and myocardial protection at the Hatter Institute at University College London, Mr Jenkins was awarded Master of Surgery from London University in 1997. He undertook his cardiothoracic surgical training in West London at Harefield, Hammersmith and St George’s hospitals, and was appointed as Consultant at Papworth Hospital in 2001. Mr Jenkins has experience in all aspects of adult cardiac surgery. Specialist experience includes surgical treatment of pulmonary hypertension, heart and lung transplantation, and mechanical circulatory support including extracorporeal membrane oxygenation (ECMO). In 2004, he became director of the UK national pulmonary endarterectomy programme (PEA) for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH). He is an executive board member of the International CTEPH Association. He is a member of the scientific board of the World Symposium Pulmonary Hypertension Association. He is currently divisional director for surgery and transplantation at Royal Papworth hospital. His research interests are related to myocardial protection, pulmonary hypertension and PEA surgery. He is a member of Society for Cardiothoracic Surgery in GB&I, European Association of Cardiothoracic Surgery, International Society for Heart and Lung Transplantation and the American Association of Thoracic Surgery.